文献速递呼吸危重症与机械通气

黏液活性药物用于危重症急性呼吸衰竭:系统综述与荟萃分析

Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis.
PubMed 文献 · Thorax · 2020-06-08

荟萃分析显示黏液活性药物未缩短机械通气时间,也未改善死亡率、住院时间或无呼吸机天数,但ICU住院时间有所缩短,证据质量均为极低。结论不支持在危重症急性呼吸衰竭患者中常规使用黏液活性药物。

要点

  • 黏液活性药物未缩短急性呼吸衰竭患者的机械通气时间。
  • ICU住院时间在黏液活性药物组有所缩短,但证据质量极低。
  • 现有证据不支持危重症急性呼吸衰竭患者常规使用黏液活性药物。

核心结论

  • 研究结果不支持在危重症急性呼吸衰竭患者中使用黏液活性药物。
  • 现有证据质量低,需要高质量随机对照试验明确特定黏液活性药物的作用。

研究设计与样本

  • 系统综述与荟萃分析,检索电子及灰色文献至2020年1月。
  • 纳入试验涉及四种不同的黏液活性药物,对照为安慰剂或标准治疗。
  • 采用随机效应模型进行荟萃分析,并使用GRADE评估证据确定性。

主要发现

  • 黏液活性药物对机械通气时间无影响(7项试验,均数差-1.34,95%CI -2.97至0.29,I2=82%,极低确定性)。
  • 黏液活性药物对死亡率、住院时间和无呼吸机天数均无影响。
  • 黏液活性药物组ICU住院时间缩短(10项试验,均数差-3.22,95%CI -5.49至-0.96,I2=89%,极低确定性)。

临床怎么用

  • 当前证据不支持在危重症急性呼吸衰竭患者中常规使用黏液活性药物。
  • 临床决策应结合极低证据质量,谨慎评估个体化使用黏液活性药物的获益与风险。

局限性

  • 现有证据质量低,主要结局的确定性均为极低。
  • 纳入试验间存在显著异质性(机械通气时间I2=82%,ICU住院时间I2=89%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Acute respiratory failure (ARF) is a common cause of admission to intensive care units (ICUs). Mucoactive agents are medications that promote mucus clearance and are frequently administered in patients with ARF, despite a lack of evidence to underpin clinical decision making. The aim of this systematic review was to determine if the use of mucoactive agents in patients with ARF improves clinical outcomes. METHODS: We searched electronic and grey literature (January 2020). Two reviewers independently screened, selected, extracted data and quality assessed studies. We included trials of adults receiving ventilatory support for ARF and involving at least one mucoactive agent compared with placebo or standard care. Outcomes included duration of mechanical ventilation. Meta-analysis was undertaken using random-effects modelling and certainty of the evidence was assessed using Grades of Recommendation, Assessment, Development and Evaluation. RESULTS: Thirteen randomised controlled trials were included (1712 patients), investigating four different mucoactive agents. Mucoactive agents showed no effect on duration of mechanical ventilation (seven trials, mean difference (MD) -1.34, 95% CI -2.97 to 0.29, I2=82%, very low certainty) or mortality, hospital stay and ventilator-free days. There was an effect on reducing ICU length of stay in the mucoactive agent groups (10 trials, MD -3.22, 95% CI -5.49 to -0.96, I2=89%, very low certainty). CONCLUSION: Our findings do not support the use of mucoactive agents in critically ill patients with ARF. The existing evidence is of low quality. High-quality randomised controlled trials are needed to determine the role of specific mucoactive agents in critically ill patients with ARF. PROSPERO REGISTRATION NUMBER: CRD42018095408.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Anand R, McAuley DF, Blackwood B, et al. Mucoactive agents for acute respiratory failure in the critically ill: a systematic review and meta-analysis. Thorax. 2020. PMID: 32513777. doi:10.1136/thoraxjnl-2019-214355

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。